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Background: The present study demonstrates the expression of intermedin (IMD) and its receptor components in
the uterus of the female rat during the estrous cycle and its effect on uterine contraction.
Methods: The gene expression level of intermedin and its receptor components and the peptide level of
intermedin were studied by real-time RT-PCR and enzyme immunoassay (EIA) respectively. The separation of
precursor and mature IMD was studied by gel filtration chromatography and EIA. The localization of IMD in the
uterus was investigated by immunohistochemistry. The effect of IMD on in vitro uterine contraction was studied by
organ bath technique.
Results: Uterine mRNAs of Imd and its receptor components and IMD levels displayed cyclic changes across the
estrous cycle. Imd mRNA level was the highest at proestrus while the IMD level was the highest at diestrus. IMD was
found in the luminal and glandular epithelia and IMD treatment significantly reduced the amplitude and frequency of
uterine contraction but not the basal tone. Both calcitonin gene-related peptide (CGRP) receptor antagonist hCGRP8-
37 and adrenomedullin (ADM) receptor antagonist hADM22-52 partially abolished the inhibitory effect of IMD on
uterine contraction while the specific IMD receptor antagonist hIMD17-47 completely blocked the actions. The enzyme
inhibitors of NO (L-NAME) and PI3K (Wortmannin) pathways diminished the IMD effects on uterine contraction while
the cAMP/PKA blocker, KT5720, had no effect, indicating an involvement of NO and PI3K/Akt but not PKA.
Conclusions: IMD and the gene expression of its receptor components are differentially regulated in the uterus during
the estrous cycle and IMD inhibits uterine contraction by decreasing the amplitude and frequency.
Keywords: Intermedin, Estrous cycle, Uterine contractionBackground
Intermedin (IMD), calcitonin, calcitonin gene-related
peptide (CGRP), adrenomedullin (ADM), and amylin, all
belong to the calcitonin/calcitonin gene-related peptide
family [1-7]. IMD (also known as adrenomedullin 2 or
ADM2), evolved early in vertebrates, is a 47-amino-acid
peptide sharing about 28% and <20% homology with
ADM and CGRP respectively in the middle region of the
peptides [2,3]. Similar to ADM, IMD signals through* Correspondence: ftang@hkucc.hku.hk
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reproduction in any medium, provided the orthe calcitonin receptor-like receptor (CRLR)/receptor
activity-modifying proteins (RAMPs) receptor complexes
[1-3]. However, ADM shows a preferential stimulation
of receptors formed by the coexpression of CRLR with
RAMP2 or RAMP3, whereas IMD is a nonselective
agonist for all these receptors [1-3].
Produced from the prointermedin molecule are three
molecular species of IMD which are biologically active
i.e. IMD1-53, IMD1-47 and IMD8-47[7]. IMD has several
functions similar to those of ADM. Both IMD and ADM
are potent vasodilators [2,8,9] and are anorexogenic
[2,4,10]. Both suppress stomach emptying [2,11,12] and
increase circulating prolactin levels [2,13,14]. However,
IMD also has its own effects not shared by ADM
[15-21]. The effects of IMD on the cardiovasculartd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Gene primer sequences and GenBank accession number of rat for the real-time PCR
Genes Primer Sequences GenBank Accession Number Product Size (bp)
Imd F: 50-GCTGATGGTCACGGTAAC-30 NM_201426.1 122
R: 50-CGCTGGAAGGAATCTTGG-30
Crlr F: 50-CCAAACAGACTTGGGAGTCACTAGG-30 NM_012717.1 323
R: 50- GCTGTCTTCTCTTTCTCATGCGTGC-30
Ramp1 F: 50- CACTCACTGCACCAAACTCGTG-30 NM_031645.1 196
R: 50- CAGTCATGAGCAGTGTGACCGTAA-30
Ramp2 F: 50- AGGTATTACAGCAACCTGCGGT-30 NM_031646.1 163
R: 50- ACATCCTCTGGGGGATCGGAGA-30
Ramp3 F: 50- ACCTGTCGGAGTTCATCGTG-30 NM_020100.2 180
R: 50- ACTTCATCCGGGGGGTCTTC-30
Actb F: 50- GGAAATCGTGCGTGACATTA-30 NM_031144.2 183
R: 50- AGGAAGGAAGGCTGGAAGAG-30
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whereas the study of IMD in reproduction has been
confined to oocyte regulation [22], trophoblast invasion
and migration [15,19], and embryonic development [20].
Both uterine ADM expression [23,24] and the re-
sponse of uterine contraction to ADM [25,26] have been
investigated. Uterine endometrium has been shown to
have more ADM than the myometrium in rats [23], and
in humans [27]. Rat uterine endometrial ADM expres-
sion peaks at proestrus and estrus and is regulated by es-
trogen [23,24].
Our laboratory has previously investigated the expression
and functions of ADM in the reproductive system [28-38].




Figure 1 Imd mRNA and IMD levels in the uterus across estrous
cycle. n=6, 6, 7, and 9 for the four stages respectively. The mRNA
levels were normalized to Actb mRNAs, and each value represents
the mean ± SEM. * P<0.01.ADM change during the estrous cycle [33]. ADM inhibits
ovarian steroidogenesis [33], stimulates ciliary beating but
inhibits muscle contraction in the oviduct [35], and plays
important roles in pregnancy [34,36]. As ADM is known to
inhibit uterine contraction [25,26], we have investigated the
changes of IMD gene expression and peptide levels in the
uterus during the estrous cycle and its effect on spontan-
eous uterine contraction to understand the possible roles of
IMD in the uterus.
Methods
Animals
Female Sprague–Dawley (SD) rats (12–13 wk) were
obtained from the Laboratory Animal Unit, LKS Faculty
of Medicine, the University of Hong Kong. The rats were
housed at a constant temperature and humidity, under a
12-h light–dark cycle (dark period 07:00h to 19:00h),
with water and rat chow ad libitum. Vaginal smears
were obtained daily from 36 rats, and 28 rats that
showed a regular 4-day estrous cycle were included in
this study. Staging of the cycle into estrus and diestrus
was based on the cytology of the vaginal smear. All rats
were killed between 10:00 a.m. and 12:00 noon and the
uteri were collected and snap-frozen in liquid nitrogen
for storage at −80°C until further analysis. Immature rats
injected with gonadotropin were used for the contrac-
tion study (please see a later section). All procedures
had been approved by the Committee on the Use of Live
Animals for Teaching and Research, the University of
Hong Kong.
RT-PCR of Imd, Crlr, and Ramps
Total RNA of the uterus was obtained by homogenization
in TRIZOL reagent (Life Technologies, Carlsbad, CA,
USA) using a polytron (Kinematica, Switzerland) [34] and
subjected to RT-PCR. RNA samples (5 μg) were reverse








































Figure 2 Expression of uterine Crlr, Ramp1, Ramp2, and Ramp3 mRNAs across estrous cycle. n=6, 6, 7, and 9 for the four stages
respectively, * P<0.05 compared with the proestrus stage, ** P<0.05 compared with all the other stages.
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Carlsbad, CA). The real time RT-PCR technique has been
previously described [35]. Polymerase chain reactions
(PCR) were conducted by an iCycler iQ real-time PCR de-
tection system (Bio-Rad Laboratories, Hercules, CA, USA)
using iQ SYBR Green Supermix (Bio-Rad Laboratories,
Hercule, CA). Three house-keeping genes (ribosomal pro-
tein L19, β-actin, and 18S ribosomal RNA) were tested and
β-actin (Actb) was used as an internal standard based on its
uniform expression across the groups. Standard curves for
each primer pair were prepared by the serial dilution of
cDNA to determine the PCR efficiency. The PCR
efficiencies for Imd, Crlr, Ramp1, Ramp2, Ramp3 and ActbFigure 3 Bio-gel P30 filtration chromatograms of the uterine
extracts at estrus (A) and diestrus (B). Mature IMD was eluted at
fraction 25 and was similar in size to IMD1-47. The arrows indicate
the positions where IMD1-53 (fraction 22), IMD1-47 (fraction 25) and
IMD8-47 (fraction 27) were eluted. The peak ratios of IMD precursor:
IMD1-47 are approximately 1:2 at estrus and 2:1 at diestrus.(β-actin used as an internal standard) were all above 0.95.
The relative gene expression levels were then analyzed by
the ΔΔCt method [39], where Ct is the cycle threshold. The
reaction mixtures contained 10 μl iQ SYBR Green
Supermix (Bio-Rad Laboratories, Hercules, CA, USA), 2 μl
template cDNA, 100 nM of each primer, and DNase-free
water (Life Technologies, Carlsbad, CA, USA) to a final
volume of 20 μl. Cycle conditions were 95°C for 5 min,
followed by a maximum of 40 cycles of 95°C for 15 sec,
59°C for 15 sec, and 72°C for 15 sec, and extension at 72°C
for 10 minutes. The reaction was completed with a dissoci-
ation step for melting point analysis with 50°C to 95°C (in
increments of 0.5°C) for 10 sec each. The design of the
primers was based on the published sequences (The details
of the primers used and the sizes of the amplicons are
shown in Table 1). Melt curve analysis for each primer
showed only one peak for each product. The identities of
all the PCR products were confirmed by gene sequencing
(Tech Dragon Limited, Hong Kong).
Measurement of IMD in the uterus
Each tissue sample (0.03 g) was homogenized in 3 ml 2N
acetic acid (1 ml/0.01 g tissue, BDH Laboratory Supplies,
Poole, England) and then boiled for 10 min. A 50-μl aliquot
was taken for the protein assay and the remaining hom-
ogenate was centrifuged at 18600 X g for 20 min at 4°C
(Sorvall SM 24; Thermo Fisher Scientific, Inc., Waltham,
MA). The supernatants were all lyophilized and stored
at −20°C until assay.
The lyophilized tissue samples were reconstituted in 1X
IMD assay buffer. IMD level was measured with an IMD
(1–50) (human) EIA kit (Phoenix Pharmaceuticals, Inc.,
Burlingame, CA, USA). The minimum detectable concen-
tration was 0.26 ng/ml and the range was 0-100 ng/ml. The
intra-assay and inter-assay coefficients of variation were
<10% and <15% respectively. The amount of protein in
each sample was measured with a protein assay reagent
(BioRad, Hercules, CA, USA) spectrophotometrically at
595 nm (LKB Ultraspec II; Biochem, Berlin, Germany). The
immunoreactive IMD was expressed as pg/mg protein.
Figure 4 Immunohistochemical study of IMD in the uterus. Positive immunostaining at the luminal epithelium (A) and glandular epithelium
(B) at both estrus (1) and diestrus (2); negative control without primary antibody (C).
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The tissues were extracted with a polytron in 1N acetic
acid (BHD Laboratory Supplies, Poole, England) on ice
(see above). A 50-μl aliquot of the homogenate was
stored at −20°C until protein assay. The lyophilized tis-
sue samples were reconstituted in Milli-Q water and
centrifuged at 13000 rpm for 20 min at 4°C. Glacial
acetic acid (96%) (Sigma, St. Louis, MO, USA) was
added to the supernatant to a final concentration of 1 N
acetic acid. The samples (in 500 μl of 1 N acetic acid)
were then loaded on a Bio-gel P30 (Bio-Rad, Hercules,
CA, USA) column (0.9 X 60 cm) and the column was
eluted with 1N acetic acid at a flow rate of 1 ml/10 min
for a total of 400 min. One-millilitre fractions werelyophilized and measured for IMD immunoreactivities
as stated before. The level of immunoreactive IMD was
expressed in terms of pg/ml of fraction/mg protein.
Authentic IMD1-53, IMD1-47 and IMD8-47 (1 ng each,
Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA)
were loaded on the same column as markers.Immunohistochemistry
To localize IMD in the uterus, a Vectastain ABC kit
(Vector Laboratories, Burlingame, CA, USA) was used
for the avidin-biotin histochemical staining procedure.
The uterine tissues were fixed in neutral buffered forma-
lin overnight. Paraffin-embedded sections of 5 μM
Control E                                    1 M KT5720                         100nM IMD
Control F                                      100 M L-NAME                 100nM IMD




Control  A 100nM IMD
Control B                                       1 M hADM22-52 100nM IMD
Control  C                                      1 M hCGRP8-37 100nM IMD







Figure 5 Representative tracings of rat uterine muscular contraction in vitro. Treatment of IMD alone (A), and together with receptor
blockers hADM22-52 (B), hCGRP8-37 (C), or hIMD17-47 (D), or enzyme inhibitors of PKA (KT5720) (E), NO synthase (L-NAME) (F), or PI3K
(Wortmannin)(G).
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with 3% hydrogen peroxide in phosphate buffer saline
for 30 min, followed by overnight incubation with
1:1000 diluted primary antibody of IMD (Phoenix
Pharmaceuticals, Inc., Burlingame, CA, USA) at 4°C.
After washing, 1:200 biotinylated secondary antibody
was added, followed by preformed ABC reagent (Rabbit
ABC Staining System, Santa Cruz, U.S.A.). Diami-
nobenzidine was used to visualize the avidin-biotin-per-
oxidase complex for 5 to 10 min.
In vitro contraction experiment by an organ-bath
technique
Immature female SD rats (21–23 days) were treated with
30 IU pregnant mare’s serum gonadotropin (PMSG)48 h prior to the collection of tissues to simulate the es-
trus stage (when the spontaneous contraction is the
greatest). Uteri from the rats were isolated and rinsed in
Kreb’s solution (115mM NaCl, 4.7mM KCl, 1mM
MgSO4, 15mM NaHCO3, 1.2mM NaH2PO4, 10.5mM
glucose, and 1.6mM CaCl2) immediately [25,26,35]. The
entire uterus [25] was then tied, via silk threads, to a tis-
sue holder in a 10-ml organ bath containing Kreb’s solu-
tion aerated with a mixture of oxygen and carbon
dioxide (95:5%) at a constant temperature of 37°C. The
tissue holder was attached to a force transducer coupled
to a graph recorder. As a pilot study using 1, 10 and 100
nM IMD indicated that the uterine preparation only res-
ponded to 100 nM IMD, the response to 100 nM IMD









































Figure 6 The effects of IMD receptor antagonists on the inhibition of uterine contraction by IMD. Decreased amplitude (A) and frequency
(B) were observed after IMD treatment. Both hADM22-52 and hCGRP8-37 partially inhibited IMD actions. hIMD17-47 completely blocked the
relaxation effect of IMD on both the contraction amplitude (A) and frequency (B). n=6 for all treatments. Data are presented as mean±SEM.
*P<0.01 vs control or blocker alone, ** P<0.01 vs IMD, #P<0.01 vs hADM22-52+IMD or hCGRP8-37+IMD.
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preincubated with 1 μM hADM22-52 (ADM receptor an-
tagonist), hCGRP8-37 (CGRP receptor antagonist), or
hIMD17-47 (IMD receptor antagonist) or the vehicle for
1h, before the addition of 100 nM IMD. For the signal-
ing pathways, the uteri were preincubated with KT5720
(1 μM, protein kinase A (PKA) inhibitor), N-nitro-L-ar-
ginine methyl ester (L-NAME) (100 μM, nitric oxide
(NO) synthase inhibitor), or Wortmannin (1 μM, serine-
threonine kinase/phosphoinositide 3-kinase (Akt/PI3K)
inhibitor) (all from Sigma Chemicals, St. Louise, MO,
USA.) before IMD (100 nM) was added.
Statistical analysis
All the data were expressed as mean ± standard error of
the mean (SEM), and statistical significance was assessed
by one-way analysis of variance (ANOVA) followed
by Student-Newman-Keuls (SNK) test for post hoc
comparisons, with P<0.05 taken as significant.
Results
IMD immunoreactivity and mRNA level of Imd
The levels of IMD and Imd mRNA in the uterus of cyc-
ling rats were estimated by IMD EIA and real-time RT-PCR respectively, and the results are shown in Figure 1.
The Imd mRNA level at the proestrus stage was taken
as 1 and it was higher than those at estrus and diestrus
(P<0.01), with no difference between estrus and diestrus.
The peptide level of IMD was higher at diestrus than
those at proestrus and estrus (P<0.01).
mRNA expression of Crlr and Ramps in cycling rats
The Crlr, Ramp1, Ramp2, and Ramp3 mRNA levels
estimated by real-time RT-PCR are shown in Figure 2.
The Crlr mRNA level was significantly lower at estrus
than that at proestrus (P<0.05) while the Ramp2 level
was lower at metestrus than all the other stages
(P<0.05). No changes were observed for Ramp1 and
Ramp3 mRNA levels.
Gel filtration chromatographic analysis of the uterus
At both the estrous (n=5) and diestrous stages (n=5),
two immunoreactive IMD peaks were observed on the
gel filtration chromatograms at fractions 15 and 25. At
estrus, there was a higher peak of IMD than the IMD
precursor while at diestrus, a predominant peak of IMD
precursor and a smaller peak of IMD were seen












































Figure 7 The effects of inhibitors in signaling pathways on the suppression of uterine contraction by IMD. Decreased amplitude (A) and
frequency (B) were observed after the IMD treatment. Both L-NAME and Wortmannin partially blocked IMD actions (A and B). KT5720 had no
effects on uterine contraction mediated by IMD. *P<0.01 vs control or inhibitor alone, **P<0.01 vs IMD, #P<0.01 vs L-NAME+ IMD
or Wortmannin+IMD.
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and IMD8-47 were eluted at fractions 22, 25 and 27 re-
spectively, the low molecular peak in the sample
corresponded to IMD1-47.
Immunohistochemical study of IMD
Positive immunostaining was observed in the rat uterus
at both estrus and diestrus in the luminal and glandular
epithelial cells with similar intensities at the two stages
(Figure 4).
Effects of IMD and its receptor antagonists and inhibitors
on uterine contraction
Representative tracings of the rat uteri treated with
IMD, receptor antagonists and signaling pathways inhi-
bitors are shown in Figure 5. IMD inhibited uterine con-
traction in both frequency and amplitude (Figure 5A).
Treatment of rat uteri with IMD significantly lowered
the amplitude and frequency of contraction by 33.67
±0.78% and 20.34 ± 1.33% respectively (P<0.05, Figure 6A
and B) but had no effects on the basal tone (results
not shown). Both hADM22-52 and hCGRP8-37 partiallyblocked the action of IMD on the amplitude (Figure 5B
and C) and the amplitude decreased only by 16.42 ±
2.01% and 20.27 ± 1.26% respectively (vs 33.67 ± 0.78%
for IMD alone, P<0.05, Figure 6A). Only hADM22-52 but
not the hCGRP8-37 partially blocked the IMD action on
frequency and the decrease was only 12.42 ± 1.01% (vs
20.34 ± 1.33% for IMD alone, P<0.05, Figure 6B).
hIMD17-47 completely blocked the relaxation effect of
IMD on both amplitude and frequency (Figures 5D, 6A
and B). The use of KT5720 did not alter the responses
of the contraction amplitude and frequency to IMD
(Figure 5E) while the effects of IMD were partially inhibited
by both L-NAME and Wortmannin (Figure 5F and G). In
the presence of L-NAME and Wortmannin IMD decreased
the amplitude by 19.13 ± 1.27 and 23.28 ± 1.80% (vs 33.67
± 0.78% for IMD alone, P<0.05, Figure 7A) and the fre-
quency by 15.85 ± 2.2 and 16.92 ± 5.2% (vs 20.34 ± 1.33%
for IMD alone, P<0.05, Figure 7B).
Discussion
We have here demonstrated the changes of uterine IMD
levels in the estrous cycle and the effect of IMD on rat
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possible roles of IMD in the female reproductive tract.
IMD decreased uterine contraction, in line with the
findings for ADM [25,26].Our study also confirmed that
Crlr, Ramp1, Ramp2, and Ramp3 are expressed in the
uterus [26], suggesting that both ADM and CGRP
receptors are present in this organ. Uterine IMD pep
tide level was higher at diestrus than at estrus with
no change in gene expression. However, according to
the gel filtration chromatogram, much of the IMD
immunoreactivity at diestrus was due to the precursor
and the amount of IMD1-47 was actually lower than at
estrus. The relative abundance of the precursor IMD at
diestrus may be explained by the decreased processing
of the precursor protein or the increased secretion of
the active IMD. As the Imd mRNA level at diestrus was
not higher than at estrus, an increase in synthesis with a
concomitant increase in release appears to be less likely.
Rather, the smaller IMD peak at diestrus may be due to
the decrease in its formation from the precursor. Our
results suggest there is a difference in the proteolytic
processing of the IMD precursor molecule. Regardless of
the cause, an increase in the IMD1-47 at estrus would
mean a greater IMD action compared with diestrus. This
may be related to uterine contraction (the present study)
or angiogenesis as intermedin is an angiogenic growth
factor [40]. The significance of an increase of Imd
mRNA at proestrus remains unclear.
We were able to demonstrate for the first time that
IMD inhibited spontaneous uterine contraction in rat by
reducing the contraction amplitude and frequency by
33.67 and 20.34% respectively. The magnitude of inhib-
ition was similar to that reported for ADM on galanin-
induced contraction [25], where the entire uterus was
used, and was less than that reported for ADM on basal
contraction [26], where uterine strips were used. This in-
hibitory effect of IMD was reversed by both ADM and
CGRP receptor antagonists, as was previously reported
for ADM [26]. However, there is one minor difference
between our study and the study of Yanagita et al. [26]
in the way to achieve synchronization of the physio-
logical state in the female rat. We injected the immature
female SD rats with PMSG while Yanagita et al. in-
jected the mature female SD rats with estradiol, but both
methods synchronized the rats to the estrous stage. This
inhibitory effect was reported at estrus when the
IMD1-47 level was higher and may synergize with the in-
hibitory effect of ADM.
We have not studied the IMD effects in induced uter-
ine contraction. In galanin-induced contraction in the
rat, ADM inhibited contraction via CGRP receptor only
[25]. CGRP inhibited galanin-induced [25] and substance
P-induced contraction in the rat [41], and KCl-induced
contraction in the human [42] and these effects weremediated by the CGRP receptor. In some of the CGRP
actions on the uterus, the NO pathway was involved
[43], but not in others [44].
In this study, both hADM22-52 and hCGRP8-37 partially
blocked the inhibitory effect of IMD on rat uterine con-
traction while hIMD17-47 exhibited complete inhibition.
These results suggest that IMD modulate uterine con-
traction mostly by specific IMD receptor and partially by
CGRP and ADM receptors. In addition, our study has
shown that both NO and PI3K pathways are involved in
IMD mediated uterine contraction. The use of L-NAME
(NO blocker) and Wortmannin (PI3K blocker) signifi-
cantly reduced the decreases in amplitude and frequency
induced by IMD but KT5720 (PKA blocker) did not
alter the IMD action. The L-NAME inhibition may be
mediated by PKG, which is activated by cGMP in the
NO pathway leading to the dephosphorylation of myosin
light chain to relax the uterine smooth muscle [43]. An-
other NO-mediated IMD effect on contraction has been
reported in the rat papillary muscle [45]. The PI3K path-
way for inhibiting smooth muscle contraction has also
been reported in gastrointestinal smooth muscles [46]
and an involvement of PI3K pathway for an IMD effect
can be found in endoplasmic reticulum stress [21]. The
cAMP-PKA system is not involved as the use of PKA
blocker had no effect on IMD actions although the ele-
vation of cAMP production was one of the characteristic
features in the early study of IMD [2].
Conclusions
In conclusion, IMD and the gene expression of its recep-
tor components are differentially expressed in the uterus
across the estrous cycle. IMD inhibits uterine contrac-
tion by decreasing the amplitude and frequency. This in-
hibitory effect at estrus may synergize with the
inhibitory effect of ADM when the IMD1-47 level was
higher.
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